# Addressing Treatment Switching Bias with G-methods: Exploring the Impact of Model Specification

Amani Al Tawil*[1,2], Sean McGrath[3], Robin Ristl†[4], and Ulrich Mansmann†[1,2]

[1] *Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, Ludwig-Maximilians-Universität München*
[2] *Pettenkofer School of Public Health, Faculty of Medicine, Ludwig-Maximilians-Universität München*
[3] *Department of Biostatistics, Harvard T.H. Chan School of Public Health*
[4] *Center for Medical Data Science, Medical University of Vienna*

## Electronic Supplementary Material 4

### Covariates used in the inverse probability of censoring weights and parametric gformula methods

*Correspondence: altawil@ibe.med.uni-muenchen.de
†Equally contributed

# Tables

**Table S3: Covariates used in the inverse probability of censoring weights and parametric gformula methods**

| | Covariates | Abbreviations |
|---|---|---|
| **Baseline covariates** | Age | $AGE, AGE^2, AGE^S$ |
| | Sex | $SEX_2$ |
| | Race | $RACE_2$ |
| | Initial diagnosis stage | $IDS_4$ |
| | Measurable intracranial Central Nervous System disease | $ICS_2$ |
| | Lung involvement at study entry | $LI_4$ |
| | ECOG score | $ECOG_2$ |
| | Strata at randomization* | $ST_4$ |
| | Smoking history | $SM_2$ |
| | Prior radiation therapy | $RT_2$ |
| **Time-varying covariates** | Follow-up time | $FUT, FUT^2, FUT^S$ |
| | ECOG score | $ECOG_2, ECOG_3$ |
| | Target-lesion size | $TLS, TLS^2, TLS^S$ |
| | Intracranial disease progression | $IDP_2$ |
| | Disease progression | $DP_2$ |
| | Time to disease progression | $TDP, TDP^2, TDP^S$ |
| | Treatment | $A_2$ |

**Numerical Variables** are labeled as variablename$^n$, where $n$ indicates the type of transformation applied:
1: linear term, 2: quadratic term, $S$: spline transformation.
**Categorical Variables** are labeled as variablename$_n$, where $n$ indicates the number of categories.
*Strata at randomization include baseline brain metastases and previous chemotherapy